Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $3.1 million.

  • Akebia Therapeutics' Receivables - Other rose 6767.12% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 6767.12%. This contributed to the annual value of $2.0 million for FY2024, which is 3969.4% down from last year.
  • As of Q3 2025, Akebia Therapeutics' Receivables - Other stood at $3.1 million, which was up 6767.12% from $5.4 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Receivables - Other ranged from a high of $56.6 million in Q2 2022 and a low of $417000.0 during Q1 2023
  • Over the past 5 years, Akebia Therapeutics' median Receivables - Other value was $2.8 million (recorded in 2021), while the average stood at $8.3 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first soared by 191015.26% in 2022, then tumbled by 9907.29% in 2023.
  • Over the past 5 years, Akebia Therapeutics' Receivables - Other (Quarter) stood at $19.1 million in 2021, then tumbled by 90.04% to $1.9 million in 2022, then surged by 75.33% to $3.3 million in 2023, then tumbled by 39.69% to $2.0 million in 2024, then skyrocketed by 52.24% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $5.4 million for Q2 2025, and $1.6 million during Q1 2025.